더바이오 11월 3일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=675](https://www.thebionews.net/edit/webzine.html?idxno=675) ● 셀트리온·삼성에피스, ‘키트루다’ 무효심판 다른 셈법…핵심은 9개월 ‘우판권’ [https://www.thebionews.net/news/articleView.html?idxno=29758](https://www.thebionews.net/news/articleView.html?idxno=29758) ● 임델트라·파드셉 병용 연이어 성공한 ‘임핀지’…알테오젠, SC 플랫폼 ‘활짝’ [https://www.thebionews.net/news/articleView.html?idxno=29759](https://www.thebionews.net/news/articleView.html?idxno=29759) ● 中·獨 ‘바이오시밀러’ 동맹…최대 37종 개발 협력에 삼성·셀트리온 경쟁 가열 [https://www.thebionews.net/news/articleView.html?idxno=29762](https://www.thebionews.net/news/articleView.html?idxno=29762) ● 中 허치메드, MET 증폭 폐암에 ‘오파티스·타그리소’ 병용 유럽·日 허가 신청 [https://www.thebionews.net/news/articleView.html?idxno=29761](https://www.thebionews.net/news/articleView.html?idxno=29761) ● [컨콜] 사노피, 아델 ‘ADEL-Y01’ 협력 유지…SK바사 ‘GBP410’ 결과 눈앞 [https://www.thebionews.net/news/articleView.html?idxno=29785](https://www.thebionews.net/news/articleView.html?idxno=29785) ● 美, ‘세포유전자치료제 품질관리 지침’ 15년만에 개정…전 주기 품질관리 강화 [https://www.thebionews.net/news/articleView.html?idxno=29786](https://www.thebionews.net/news/articleView.html?idxno=29786) ● LG화학, 美 리듬과 희귀 비만신약 기술수출 규모 확대…총 1조1500억원 [https://www.thebionews.net/news/articleView.html?idxno=29783](https://www.thebionews.net/news/articleView.html?idxno=29783) ● 퍼스트바이오, 100억원 규모 투자 유치 완료…“SK바이오팜도 SI로 참여” [https://www.thebionews.net/news/articleView.html?idxno=29776](https://www.thebionews.net/news/articleView.html?idxno=29776) ● “임상시험서도 ‘종이문서 시대’ 저문다…AI 전환 준비해야” [https://www.thebionews.net/news/articleView.html?idxno=29792](https://www.thebionews.net/news/articleView.html?idxno=29792) ● 디앤디파마텍, 간섬유화 신약 후보 내년 1상 진입…“경구 펩타이드 개발 확대” [https://www.thebionews.net/news/articleView.html?idxno=29790](https://www.thebionews.net/news/articleView.html?idxno=29790) ● 애브비·中 브리즈, 1조원 규모 ‘편두통’ 신약 협력 진전…초기 마일스톤 달성 [https://www.thebionews.net/news/articleView.html?idxno=29787](https://www.thebionews.net/news/articleView.html?idxno=29787) ● 유니큐어, ‘AMT-130’ 헌팅턴병 유전자치료제 美 우선심사…내년 5월 결론 [https://www.thebionews.net/news/articleView.html?idxno=29788](https://www.thebionews.net/news/articleView.html?idxno=29788) ● 알테오젠, 분기 매출 첫 1000억원 돌파…영업익 789억원 ‘역대 최대’ [https://www.thebionews.net/news/articleView.html?idxno=29784](https://www.thebionews.net/news/articleView.html?idxno=29784) ● GC녹십자, ‘국민성장펀드’ 1700억원 자금 조달 승인…‘20% SCIG’ 개발 속도 [https://www.thebionews.net/news/articleView.html?idxno=29770](https://www.thebionews.net/news/articleView.html?idxno=29770) ● 삼성바이오로직스, 글로벌 제약사와 4343억원 규모 위탁생산 계약 [https://www.thebionews.net/news/articleView.html?idxno=29767](https://www.thebionews.net/news/articleView.html?idxno=29767) ● 스카이랩스, 보령과 AI 의료 데이터 플랫폼 연계…우주의학 진출 [https://www.thebionews.net/news/articleView.html?idxno=29769](https://www.thebionews.net/news/articleView.html?idxno=29769) ● 베르티스, 지씨셀과 SURF 기반 신규 타깃 발굴·세포치료제 개발 [https://www.thebionews.net/news/articleView.html?idxno=29778](https://www.thebionews.net/news/articleView.html?idxno=29778) ● 팬젠, ‘바이오유럽’ 참가…“EPO 의약품 유럽 시장 정조준” [https://www.thebionews.net/news/articleView.html?idxno=29781](https://www.thebionews.net/news/articleView.html?idxno=29781) ● 파마리서치, 주요 산부인과 학술대회 참가…‘자이너’ 학술 교류 확대 [https://www.thebionews.net/news/articleView.html?idxno=29780](https://www.thebionews.net/news/articleView.html?idxno=29780) ● 갤럭스, 신용보증기금 ‘Pre-ICON’ 선정…최대 70억원 보증 지원 확보 [https://www.thebionews.net/news/articleView.html?idxno=29774](https://www.thebionews.net/news/articleView.html?idxno=29774) ● Aprilbio takes part in ‘BIO Europe’ – “Actively pursuing strategic collaboration with global partners” [https://www.thebionews.net/news/articleView.html?idxno=29804](https://www.thebionews.net/news/articleView.html?idxno=29804) ● D&D Pharmatech takes over key pipeline from U.S. Subsidiary ‘Neuraly’ – “Strengthening business control” [https://www.thebionews.net/news/articleView.html?idxno=29803](https://www.thebionews.net/news/articleView.html?idxno=29803) ● QVIS sharpens focus on Japan's clinical quality control and pharmacovigilance market, discussing cooperation strategies with 52 companies [https://www.thebionews.net/news/articleView.html?idxno=29796](https://www.thebionews.net/news/articleView.html?idxno=29796) ● PanGen Biotech Participates in 'Bio Europe 2026', Targeting the European Market with EPO Biosimilar [https://www.thebionews.net/news/articleView.html?idxno=29801](https://www.thebionews.net/news/articleView.html?idxno=29801) ● GI Innovation and TriOar co-develop next-generation masking multispecific antibodies [https://www.thebionews.net/news/articleView.html?idxno=29800](https://www.thebionews.net/news/articleView.html?idxno=29800) ● Inventage Lab secures Phase 1 CSR for 1-month continuous drug addiction treatment, strengthening L/O foundation [https://www.thebionews.net/news/articleView.html?idxno=29799](https://www.thebionews.net/news/articleView.html?idxno=29799) ● RudaCure inks development and technology transfer deal with France's Ceva for new canine dry eye treatment [https://www.thebionews.net/news/articleView.html?idxno=29798](https://www.thebionews.net/news/articleView.html?idxno=29798) ● Bukwang Pharmaceutical teams up with Samsung Medical Center and BlueSignum to develop digital therapeutic for schizophrenia [https://www.thebionews.net/news/articleView.html?idxno=29797](https://www.thebionews.net/news/articleView.html?idxno=29797) ● Samsung Medical Center and Israel’s Alpha Tau Medical sign MOU to launch exchange and cooperation in pancreatic cancer [https://www.thebionews.net/news/articleView.html?idxno=29795](https://www.thebionews.net/news/articleView.html?idxno=29795) ● IMGT: “Ultrasound boosts pancreatic cancer drug delivery – Heads into U.S. confirmatory clinical trials, eyes KOSDAQ” [https://www.thebionews.net/news/articleView.html?idxno=29794](https://www.thebionews.net/news/articleView.html?idxno=29794) *제약바이오 11월 3일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=WoVpXjI8E5Q](https://www.youtube.com/watch?v=WoVpXjI8E5Q)